In this issue of Blood, studies by Lavallée et al and Maxson et al provide a powerful example of functional and genomic data integration to reveal unexpected correlations between genotype and phenotype in acute myeloid leukemia (AML).
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T he landscape of recurrent genetic events in AML has been elegantly unraveled in recent years 3 ; however, for most disease subsets this has not yet led to facile deployment of therapeutics targeting aberrant genetic events. The resulting gap in our ability to decipher genetic drivers versus our capacity to harness this knowledge for therapeutic advantage will require the integration of genotype information with transcriptomic, proteomic, and drug response data. The studies by Lavallée CEBPA is a transcription factor that is crucial for regulating myeloid lineage development. In particular, it has been shown to regulate expression of CSF3R, thereby promoting neutrophil differentiation. 4 Mutations in CEBPA are observed in 5% to 15% of AML patients, 3, 5, 6 and those mutations can be classified into the following 3 categories: (1) monoallelic mutation, (2) typical CEBPA bi AML (ie, biallelic mutation with one allele harboring an N-terminal frameshift or nonsense mutation and the other allele having an inframe insertion or deletion of the C terminus), and (3) for their roles in infectious diseases, innate immunity, and inflammation. [2] [3] [4] To date, it has been unclear whether reduced platelet counts
